Literature DB >> 8257125

Antibiotic treatment of experimental endocarditis due to vancomycin- and ampicillin-resistant Enterococcus faecium.

M S Whitman1, P G Pitsakis, A Zausner, L L Livornese, A J Osborne, C C Johnson, M E Levison.   

Abstract

We compared ciprofloxacin, rifampin, and gentamicin treatments, alone and in combination, for 5 days in the therapy of experimental aortic valve endocarditis in rats caused by a clinical isolate of vancomycin-resistant Enterococcus faecium. The MICs and MBCs of vancomycin, ciprofloxacin, rifampin, and gentamicin were 250 and > 1,000, 3.1 and 6.3, 0.098 and 1.6, and 12.5 and > 50 micrograms/ml, respectively. Infected rats were sacrificed after completing 5 days of therapy. Additional rats within each treatment group were followed for 5 days beyond the last dose of antibiotic therapy. Although survivals in the different groups were not significantly different after 5 days of therapy, survival was significantly better 5 days beyond the last dose of antibiotic therapy in rats treated with rifampin-containing regimens. The combination of ciprofloxacin and gentamicin was bactericidal in vitro and in vegetations from rats with enterococcal endocarditis. Rifampin alone was similarly bactericidal in vivo, but it was not significantly better than rifampin in combination with other antibiotics. Subpopulations resistant to rifampin, but not ciprofloxacin, were detected in the inoculum and in most vegetations during therapy. However, the combination of ciprofloxacin plus both gentamicin and rifampin reduced both the rifampin-susceptible and -resistant population in vegetations of 9 of 10 animals below the level of detection after 5 days of therapy. Nevertheless, a residual enterococcal population apparently remained in numbers of < 2 log10 CFU/g after 5 days of therapy, which resulted in relapse. Perhaps a longer course of therapy would have eliminated this residual population and improved efficacy.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8257125      PMCID: PMC192230          DOI: 10.1128/AAC.37.10.2069

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  18 in total

1.  Plasmid-mediated resistance to vancomycin and teicoplanin in Enterococcus faecium.

Authors:  R Leclercq; E Derlot; J Duval; P Courvalin
Journal:  N Engl J Med       Date:  1988-07-21       Impact factor: 91.245

2.  Ciprofloxacin and rifampin, alone and in combination, for therapy of experimental Staphylococcus aureus endocarditis.

Authors:  G W Kaatz; S M Seo; S L Barriere; L M Albrecht; M J Rybak
Journal:  Antimicrob Agents Chemother       Date:  1989-08       Impact factor: 5.191

Review 3.  Bacterial resistance to quinolones: mechanisms and clinical importance.

Authors:  J S Wolfson; D C Hooper
Journal:  Rev Infect Dis       Date:  1989 Jul-Aug

4.  Hospital-acquired infection with vancomycin-resistant Enterococcus faecium transmitted by electronic thermometers.

Authors:  L L Livornese; S Dias; C Samel; B Romanowski; S Taylor; P May; P Pitsakis; G Woods; D Kaye; M E Levison
Journal:  Ann Intern Med       Date:  1992-07-15       Impact factor: 25.391

5.  Antibiotic synergism in enterococcal endocarditis.

Authors:  J Carrizosa; D Kaye
Journal:  J Lab Clin Med       Date:  1976-07

6.  High-level penicillin resistance among isolates of enterococci. Implications for treatment of enterococcal infections.

Authors:  L M Bush; J Calmon; C L Cherney; M Wendeler; P Pitsakis; J Poupard; M E Levison; C C Johnson
Journal:  Ann Intern Med       Date:  1989-04-01       Impact factor: 25.391

7.  Synergistic bactericidal activity of rat serum with vancomycin against enterococci.

Authors:  M J Gold; J Calmon; M Wendeler; M E Levison; C C Johnson
Journal:  J Infect Dis       Date:  1991-06       Impact factor: 5.226

8.  In vitro activities of quinolones against enterococci resistant to penicillin-aminoglycoside synergy.

Authors:  D F Sahm; G T Koburov
Journal:  Antimicrob Agents Chemother       Date:  1989-01       Impact factor: 5.191

9.  Inducible, transferable resistance to vancomycin in Enterococcus faecalis A256.

Authors:  D M Shlaes; A Bouvet; C Devine; J H Shlaes; S al-Obeid; R Williamson
Journal:  Antimicrob Agents Chemother       Date:  1989-02       Impact factor: 5.191

10.  Recovery of resistant enterococci during vancomycin prophylaxis.

Authors:  A H Kaplan; P H Gilligan; R R Facklam
Journal:  J Clin Microbiol       Date:  1988-06       Impact factor: 5.948

View more
  9 in total

Review 1.  Vancomycin-resistant enterococci.

Authors:  Y Cetinkaya; P Falk; C G Mayhall
Journal:  Clin Microbiol Rev       Date:  2000-10       Impact factor: 26.132

Review 2.  Current perspectives on glycopeptide resistance.

Authors:  N Woodford; A P Johnson; D Morrison; D C Speller
Journal:  Clin Microbiol Rev       Date:  1995-10       Impact factor: 26.132

Review 3.  Treatment options for vancomycin-resistant enterococcal infections.

Authors:  Peter K Linden
Journal:  Drugs       Date:  2002       Impact factor: 9.546

4.  Comparative in vitro activities of trovafloxacin (CP-99,219) against 445 gram-positive isolates from patients with endocarditis and those with other bloodstream infections.

Authors:  H P Endtz; J W Mouton; J G den Hollander; N van den Braak; H A Verbrugh
Journal:  Antimicrob Agents Chemother       Date:  1997-05       Impact factor: 5.191

5.  Efficacy of Telavancin Alone and in Combination with Ampicillin in a Rat Model of Enterococcus faecalis Endocarditis.

Authors:  Truc T Tran; Vincent H Tam; Barbara E Murray; Cesar A Arias; Kavindra V Singh
Journal:  Antimicrob Agents Chemother       Date:  2017-05-24       Impact factor: 5.191

6.  Relapse of Enterococcus hirae prosthetic valve endocarditis.

Authors:  J P Talarmin; S Pineau; A Guillouzouic; D Boutoille; C Giraudeau; A Reynaud; D Lepelletier; S Corvec
Journal:  J Clin Microbiol       Date:  2011-01-19       Impact factor: 5.948

7.  Risk factors for fluoroquinolone resistance in Enterococcus urinary tract infections in hospitalized patients.

Authors:  P Rattanaumpawan; P Tolomeo; W B Bilker; N O Fishman; E Lautenbach
Journal:  Epidemiol Infect       Date:  2010-08-09       Impact factor: 2.451

8.  Activity of clinafloxacin against multidrug-resistant Enterococcus faecium.

Authors:  S Burney; D Landman; J M Quale
Journal:  Antimicrob Agents Chemother       Date:  1994-07       Impact factor: 5.191

9.  In Vitro Pharmacodynamic Analyses Help Guide the Treatment of Multidrug-Resistant Enterococcus faecium and Carbapenem-Resistant Enterobacter cloacae Bacteremia in a Liver Transplant Patient.

Authors:  Eric Wenzler; Maressa Santarossa; Kevin A Meyer; Amanda T Harrington; Gail E Reid; Nina M Clark; Fritzie S Albarillo; Zackery P Bulman
Journal:  Open Forum Infect Dis       Date:  2020-01-04       Impact factor: 3.835

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.